Real world study in Locally Advanced or Metastatic NSCLC patients, Progressed From First-line EGFR-TKI Therapy - PISCES

Study identifier:D5160R00031

ClinicalTrials.gov identifier:NCT04207775

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes in EGFR Mutation-Positive, Locally Advanced or Metastatic Chinese NSCLC patients, Who Have Progressed From First-line EGFR-TKI Therapy (PISCES)

Medical condition

locally advanced or metastatic NSCLC

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

300

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 30 Mar 2020
Primary Completion Date: 01 Sept 2023
Study Completion Date: 01 Sept 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria